Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Not Yet Recruiting NCT05667116

eVusheld Assessment reaL wORld Effectiveness at UPMC

Conditions: SARS-CoV-2, COVID-19

Sex: All

Ages: 12 Years – N/A

Enrollment: 6000

Sponsor: AstraZeneca

Summary

An AstraZeneca-sponsored observational, electronic healthcare record (EHR)-embedded retrospective cohort study to assess the real-world effectiveness of EVUSHELD against SARS-CoV-2 infection, COVID-19-related hospitalization, and other COVID-19 related outcomes in the total EUA-eligible patient population in the University of Pittsburgh Medical Center (UPMC) Health System.

Eligibility Criteria

Inclusion Criteria:Receipt of EVUSHELD under the FDA EUA for EVUSHELDEligibility for assess Evusheld use under the EUA. -Exclusion Criteria:None

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05667116). StuddyBuddy aggregates publicly available trial information.